Payment overview · 2025
General Payments
$2,803.88
148 reported records · 21 companies
Healthcare provider profile · identity verified
Clinton Hale Sutherland, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ABINGDON, VA · NPI 1487622320
Verified facts
What the public records show
CMS Open Payments records show Clinton Hale Sutherland, MD received $2,803.88 in general payments during 2025 across 148 reported records.
Novo Nordisk Inc accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Qulipta, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $491.36 | 17.5% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $345.97 | 12.3% | 23 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $299.91 | 10.7% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $268.50 | 9.6% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $255.34 | 9.1% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $192.27 | 6.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $185.46 | 6.6% | 21 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $109.97 | 3.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $105.83 | 3.8% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.95 | 2.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.26 | 2.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.96 | 2.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.64 | 2.5% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $61.65 | 2.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $59.96 | 2.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.51 | 1.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.76 | 0.8% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $22.33 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.96 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.35 | 0.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.94 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,803.88 | 148 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $326.17 | 13 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $299.91 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $268.50 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $192.27 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $181.64 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $172.14 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $171.62 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $124.38 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.38 | 17 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.99 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $109.97 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $109.13 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $105.83 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $96.03 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $81.64 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $77.95 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $77.24 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.64 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $61.65 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $61.08 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.08 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $61.08 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.08 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $59.96 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.12 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.12 | 3 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $48.59 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.07 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.50 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 133 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 75 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 139 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 355 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 323 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
323 | 89 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
133 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
396 | 96 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
139 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
355 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
396 | 96 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1052 | 294 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 929 | 279 |
| Amlodipine Besylate | Amlodipine Besylate | 858 | 242 |
| Pantoprazole Sodium | Pantoprazole Sodium | 804 | 234 |
| Omeprazole | Omeprazole | 784 | 223 |
| Gabapentin | Gabapentin | 625 | 171 |
| Losartan Potassium | Losartan Potassium | 622 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 604 | 157 |
| Lisinopril | Lisinopril | 566 | 153 |
| Metoprolol Succinate | Metoprolol Succinate | 547 | 151 |
| Tamsulosin Hcl | Tamsulosin Hcl | 479 | 135 |
| Pravastatin Sodium | Pravastatin Sodium | 398 | 108 |
| Eliquis | Apixaban | 396 | 96 |
| Trazodone Hcl | Trazodone Hcl | 385 | 122 |
| Metformin Hcl Er | Metformin Hcl | 380 | 109 |
| Escitalopram Oxalate | Escitalopram Oxalate | 365 | 104 |
| Potassium Chloride | Potassium Chloride | 357 | 108 |
| Ozempic | Semaglutide | 355 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 351 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 339 | 84 |
| Atenolol | Atenolol | 327 | 79 |
| Synthroid | Levothyroxine Sodium | 323 | 89 |
| Metformin Hcl | Metformin Hcl | 311 | 90 |
| Duloxetine Hcl | Duloxetine Hcl | 304 | 84 |
| Furosemide | Furosemide | 302 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 289 | 104 |
| Alprazolam | Alprazolam | 285 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 284 | 103 |
| Tramadol Hcl | Tramadol Hcl | 284 | 54 |
| Alendronate Sodium | Alendronate Sodium | 275 | 90 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 77 |
| Tizanidine Hcl | Tizanidine Hcl | 264 | 73 |
| Montelukast Sodium | Montelukast Sodium | 258 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 253 | 66 |
| Famotidine | Famotidine | 242 | 77 |
| Chlorthalidone | Chlorthalidone | 241 | 71 |
| Simvastatin | Simvastatin | 225 | 61 |
| Glipizide Er | Glipizide | 220 | 63 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 201 | 57 |
| Xarelto | Rivaroxaban | 201 | 42 |
| Allopurinol | Allopurinol | 190 | 48 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 189 | 45 |
| Mirtazapine | Mirtazapine | 188 | 56 |
| Meloxicam | Meloxicam | 177 | 57 |
| Clonazepam | Clonazepam | 171 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 169 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 157 | 43 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 154 | 40 |
| Ezetimibe | Ezetimibe | 149 | 43 |
| Valsartan | Valsartan | 147 | 40 |
| Finasteride | Finasteride | 144 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 143 | 36 |
| Carvedilol | Carvedilol | 142 | 45 |
| Sertraline Hcl | Sertraline Hcl | 140 | 42 |
| Mounjaro | Tirzepatide | 139 | 23 |
| Ibuprofen | Ibuprofen | 136 | 53 |
| Farxiga | Dapagliflozin Propanediol | 133 | 28 |
| Tresiba Flextouch U-100 | Insulin Degludec | 133 | 30 |
| Jardiance | Empagliflozin | 132 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 128 | 34 |
| Lorazepam | Lorazepam | 123 | 29 |
| Baclofen | Baclofen | 113 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 25 |
| Pregabalin | Pregabalin | 103 | 30 |
| Buspirone Hcl | Buspirone Hcl | 100 | 29 |
| Donepezil Hcl | Donepezil Hcl | 99 | 33 |
| Spironolactone | Spironolactone | 99 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 99 | 24 |
| Fosinopril Sodium | Fosinopril Sodium | 93 | 24 |
| Nitroglycerin | Nitroglycerin | 93 | 54 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 22 |
| Lansoprazole | Lansoprazole | 81 | 24 |
| Warfarin Sodium | Warfarin Sodium | 81 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 24 |
| Bupropion Xl | Bupropion Hcl | 76 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 28 |
| Linzess | Linaclotide | 75 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 73 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 23 |
| Prednisone | Prednisone | 68 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 16 |
| Repatha Sureclick | Evolocumab | 64 | 13 |
| Labetalol Hcl | Labetalol Hcl | 61 | 14 |
| Entresto | Sacubitril/Valsartan | 60 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 19 |
| Diazepam | Diazepam | 57 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 45 |
| Celecoxib | Celecoxib | 55 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 12 |
| Trulicity | Dulaglutide | 54 | 13 |
| Propranolol Hcl | Propranolol Hcl | 53 | 16 |
| Enalapril Maleate | Enalapril Maleate | 52 | 14 |
| Estradiol | Estradiol | 51 | 20 |
| Dutasteride | Dutasteride | 50 | 13 |
| Ketoconazole | Ketoconazole | 50 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 13 |
| Doxepin Hcl | Doxepin Hcl | 48 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 48 | 11 |
| Novolog Flexpen | Insulin Aspart | 48 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | 15 |
| Sucralfate | Sucralfate | 47 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Colestipol Hcl | Colestipol Hcl | 44 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 44 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 39 |
| Azelastine Hcl | Azelastine Hcl | 43 | 17 |
| Ramipril | Ramipril | 42 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 42 | 12 |
| Promethazine Hcl | Promethazine Hcl | 41 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 15 |
| Topiramate | Topiramate | 41 | 13 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 25 |
| Brilinta | Ticagrelor | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 16 |
| Glimepiride | Glimepiride | 39 | 11 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 33 |
| Klor-Con M10 | Potassium Chloride | 38 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 24 |
| Valacyclovir | Valacyclovir Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Ibu | Ibuprofen | 36 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Oxycontin | Oxycodone Hcl | 36 | suppressed |
| Primidone | Primidone | 36 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 14 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 11 |
| Naproxen | Naproxen | 32 | 12 |
| Ranolazine Er | Ranolazine | 32 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 26 |
| Fluconazole | Fluconazole | 26 | 18 |
| Torsemide | Torsemide | 26 | 11 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | 11 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Buprenorphine | Buprenorphine | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Epinephrine | Epinephrine | 21 | 19 |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 14 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 15 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Glipizide Xl | Glipizide | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Fluocinonide | Fluocinonide | 17 | 11 |
| Folic Acid | Folic Acid | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Savella | Milnacipran Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,803.88 · 148 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, COMIRNATY, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, HETLIOZ, JARDIANCE, Korlym, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, OTEZLA, Omnipod, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error